Institutional members access full text with Ovid®

Response to antiretroviral therapy in occult hepatitis B and HIV co-infection in West Africa

Chadwick, Davida; Stanley, Alastaira; Sarfo, Stephenb; Appiah, Lambertb; Ankcorn, Michaela; Foster, Geraldinec; Schwab, Ulid; Phillips, Richardb; Geretti, Anna M.c

doi: 10.1097/QAD.0b013e3283589879
Research Letters

This study evaluated the outcome of first-line antiretroviral therapy among 35 Ghanaians with occult HBV/HIV co-infection, comparing them over 2 years to 120 patients with HBsAg+ HBV/HIV co-infection and 230 patients without HBV co-infection. Increases in CD4 cell count and BMI were similar, whereas elevations of hepatic transaminases were more frequent in both the occult HBV and HBsAg+ patients. Occult HBV/HIV co-infection appears not to impact adversely on response to antiretroviral therapy in Ghana.

aCentre for Clinical Infection, The James Cook University Hospital, Middlesbrough, UK

bKomfo Anokye Teaching Hospital, Kumasi, Ghana

cInstitute of Global Health, University of Liverpool

dDepartment of Infection and Tropical Medicine, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK.

Correspondence to David Chadwick, Centre for Clinical Infection, The James Cook University Hospital, Marton Road, Middlesbrough, TS4 3BW, UK. Tel: +44 1642 854429; fax: +44 1642 854017; e-mail:

Received 31 May, 2012

Revised 17 July, 2012

Accepted 26 July, 2012

© 2013 Lippincott Williams & Wilkins, Inc.